Introduction
Estrogens produce biological effects by binding to two distinct estrogen receptors, ERa and ERb, that can activate or repress gene transcription (Green et al., 1986; Kuiper et al., 1996) . Most studies on gene regulation by estrogens have focused on understanding how estradiol (E 2 ) induces gene transcription (Bjornstrom and Sjoberg, 2005; Nilsson et al., 2001 ). However, transcriptional repression of cytokine genes may be an important mechanism whereby estrogens prevent inflammatory diseases associated with menopause. As estrogen levels drop after menopause, there is a greater production of cytokines (Pfeilschifter et al., 2002 ) that contribute to inflammatory conditions, such as osteoporosis (Ammann et al., 1997; Pacifici, 1996) , cardiovascular disease (Pai et al., 2004) , and Alzheimer's disease (Cacquevel et al., 2004) .
Despite the clinical importance of transcriptional repression, the mechanisms of estrogen-mediated repression of cytokine genes are poorly understood. The little that is known has been derived exclusively from transfection studies with promoters linked to reporter genes Galien and Garcia, 1997; Stein and Yang, 1995) . These studies suggest that estrogens repress genes by blocking the binding of NFkB to the promoter, but this hypothesis has not been evaluated with endogenous cytokine genes.
As transcriptional activation of proliferative genes by estrogens is associated with breast cancer (Foster et al., 2001 ) and the transcriptional repression function of ER mediates the anti-inflammatory effects of estrogens, we hypothesize that repression-selective estrogens may retain beneficial effects on bone and other tissues without promoting cancer. Thus, a greater understanding of the molecular mechanisms of transcriptional repression might lead to the discovery of estrogenic drugs that selectively trigger the repression function of ERs. Chromatin immunoprecipitation (ChiP) has been used to study how estrogens activate genes (Metivier et al., 2003; Shang et al., 2000) . Here, we used chromatin immunoprecipitation to investigate how estrogens repress transcription of the TNFa gene, because excessive TNFa production is associated with osteoporosis (Ammann et al., 1997; Nanes, 2003; Pacifici, 1996) and other inflammatory diseases (Pai et al., 2004) .
Results

E 2 Inhibits TNFa Activation of the TNFa Gene in Primary Human Osteoblasts and Stable U2OS Cell Lines
We investigated if E 2 represses TNFa activation of the TNFa gene in primary human osteoblasts. TNFa produced a large induction of TNFa mRNA, which was markedly inhibited by E 2 ( Figure 1A ). To generate a sufficient quantity of cells required to investigate the mechanisms whereby estrogens repress the transcription of the TNFa gene, we created stable U2OS osteosarcoma cell lines that express a tetracycline-inducible ERa or ERb (Kian Tee et al., 2004) . TNFa produced a large activation of the TNFa gene in U2OS-ERa and U2OS-ERb cells ( Figure 1B ). E 2 caused a time-dependent repression of TNFa induction of TNFa mRNA levels with both ERa and ERb. Maximal repression occurred after 3 hr and persisted for at least 18 hr. No repression was observed in U2OS wild-type or MDA-MB-435 cells (data not shown), which do not express ERs, demonstrating that ER mediates the repression by E 2 . Imperial Chemical Industries (ICI) 182,780 and tamoxifen did not reduce TNFa mRNA, whereas a small repression was observed with raloxifene ( Figure 1C ). Other ER isoforms such as ERa46 are expressed in osteoblasts (Denger et al., 2001) , which may exhibit different responses to E 2 and SERMs than ERa66 or ERb1 used in our studies.
To rule out that repression of the TNFa gene results from overexpression of ER, doxycycline was used to vary the levels of ERa ( Figure 1D ). Doxycycline produced a dose-dependent increase in ERa as measured by specific 3 H-E 2 binding in intact U2OS-ERa cells (Figure 1E ). Repression by E 2 was observed at 0.1 ng/ml doxycycline ( Figure 1D ), which produced 825 receptors per cell ( Figure 1E ). At 0.5 ng/ml doxycycline, E 2 produced a 60% reduction in TNFa mRNA in U2OS-ERa cells that contained 4800 receptors per cell. These levels are comparable to 1500-3300 receptors per cell expressed in primary human osteoblasts (Eriksen et al., 1988) and less than the 15,000 receptors per cell expressed in MCF-7 cells (McLaughlin et al., 1984) , which are commonly used to study how ERs activate gene transcription (Metivier et al., 2003; Shang et al., 2000) . These studies demonstrate that inducible-U2OS cell lines behave similarly to primary human osteoblasts and that repression of the TNFa gene is observed at physiological levels of ERs.
TNFa Recruits c-jun, NFkB, and Unliganded ER to the TNFa Promoter ChIP was used to identify factors that TNFa recruits to the TNFa promoter. Polymerase chain reaction (PCR) primers used spanned the TNFa-response element (TNF-RE; 2125 to 282 region), which contains a composite AP-1/NFkB element (Tzagarakis-Foster et al., 2002 ) that mediates TNFa activation and E 2 repression . U2OS cells were stably transfected with Flag-ERa or Flag-ERb to initially compare the binding of ERa and ERb with a single antibody. E 2 repressed TNFa gene expression in Flag-ERa ( Figure 1F ) and FlagERb (data not shown) cells equivalent to the inducible cells ( Figure 1B ), demonstrating that Flag-ERs behave similarly to nontagged ERs. Cells were treated for increasing times with TNFa in the absence or presence of E 2 , and then ChIP was done by using antibodies to c-jun, p50-NFkB, p65-NFkB, and the Flag epitope tag. TNFa induced recruitment of c-jun, p50-NFkB, and p65-NFkB to the TNF-RE in U2OS-Flag-ERa and U2OS-Flag-ERb cells (Figures 2A and 2B, respectively) . Unexpectedly, TNFa also recruited ERa and ERb to the TNFa gene in the absence of E 2 (Figures 2A and 2B, respectively) . Maximal recruitment of unliganded ER occurred after 3 to 4 hr of TNFa treatment, which was slower than the recruitment of c-jun and NFkB. E 2 did not alter the recruitment of c-jun, p50-NFkB, or p65-NFkB, but resulted in the apparent loss of Flag-ERa and Flag-ERb from the TNFa promoter. The disappearance of ER was not due to an unusual characteristic of the Flag-ER fusion proteins or Flag antibody, because the loss was observed with three antibodies against different epitopes of ERa and antibodies against ERb ( Figure 2C ). Furthermore, E 2 recruited ERa and ERb to the keratin 19 gene (Figures 2C), which is activated by E 2 in U2OS-ERa and U2OS-ERb cells ( Figure 2D ). TNFa did not recruit unliganded ERa or ERb to the keratin 19 gene at any time during a 4 hr time course ( Figure 2E ). These results demonstrate that TNFa recruits ER to the TNFa gene, but not to the keratin 19 gene, whereas E 2 recruited ER only to the keratin 19 gene.
Unliganded ERa Is Associated with c-jun and NFkB
To explore the mechanism by which TNFa recruits unliganded ER to the TNFa promoter, we performed coimmunoprecipitation to investigate protein-protein interactions with ERa. U2OS-ERa cells were treated with TNFa in the absence or presence of doxycycline to induce ERa. Cell extracts were immunoprecipitated with Figure 1 . E 2 Represses Transcription of the TNFa Gene in Primary Human Osteoblasts and Stable U2OS-ER Cells (A) Primary human osteoblasts (Clonetics NHOst, Cambrex) were treated with 5 ng/ml TNFa for 2 hr in the absence or presence of 100 nM E 2 for 3 hr. TNFa mRNA levels were determined by qPCR. (B) U2OS-ERa and U2OS-ERb cells were treated with 1 mg/ml doxycycline for 18 hr to induce ER expression. Cells were then treated with 5 ng/ml TNFa for 2 hr in the absence or presence of 100 nM E 2 for the indicated times and TNFa mRNA levels were determined by qPCR. (C) U2OS-ERa and U2OS-ERb cells were treated for 3 hr with 100 nM E 2 , 100 nM ICI, 100 nM raloxifene, or 1 mM tamoxifen and with 5 ng/ml TNF for 2 hr. TNFa mRNA levels were determined by qPCR. (D) U2OS-ERa cells were treated with doxycycline for 18 hr. After treatment with E 2 and TNFa, qPCR was used to measure TNFa mRNA. (E) ER binding assays were done for 2 hr at 37ºC with 3 H-E 2 in U2OS-ERa cells treated with doxycycline. (F) U2OS-Flag-tagged-ERa cells were treated with TNFa and E 2 as described above for U2OS-ERa cells. TNFa mRNA levels were determined by qPCR. Error bars represent the mean 6SEM.
antibodies to c-jun, p50-NFkB, or p65-NFkB. Western blotting analyses were done with an ERa antibody. In cells treated with TNFa and doxycycline, c-jun and NFkB coimmunoprecipitated with ERa ( Figure 2F ). No signal was observed with ERa antibodies in control cells that did not express ERa (-doxycycline). These results suggest that c-jun and NFkB form a platform to tether ER to the TNFa promoter.
Membrane receptor signaling can activate the mitogen-activated protein kinase (MAPK) pathway, which causes phosphorylation of serine (ser)-118 and ser-167 in the activation function-1 (AF-1) domain of ERa (Lannigan, 2003) . TNFa activates MAPK (Wajant et al., 2003) , suggesting that TNFa may trigger the interaction of ER with c-jun and NFkB by inducing ER phosphorylation. To examine this possibility, U2OS-ERa cells were treated with TNFa, and Western blots were performed with phospho-ERa antibodies that recognize ser-118 or ser-167. E 2 , which is known to activate MAPK (Improta-Brears et al., 1999; Kato et al., 1995; Le Goff et al., 1994) , phosphorylated both ser-118 and ser-167 ( Figure 2G , middle and lower panels, respectively).
In contrast, TNFa did not phosphorylate ser-118 and ser-167, even though ERa was present in all samples except for cells that were not treated with doxycycline (Figure 2G, upper panel) . These results demonstrate that TNFa does not activate ER by phosphorylating these two serines.
Unliganded ER Acts as a Coactivator by Potentiating TNFa-Induced Transcription of the TNFa Gene The significance of unliganded ER interaction with the TNFa gene was studied in U2OS-ERa cells. The induction of ERa by doxycycline was associated with a much greater TNFa stimulation of TNFa mRNA (Figure 3A) . The potentiation required ER, because no potentiation of TNFa activation was observed in wildtype U2OS cells treated with doxycycline ( Figure 3A ). To rule out that unliganded ER potentiation is not due to the selection of an anomalous stable cell line, an adenovirus (Ad) was used to introduce ERa into wild-type U2OS cells, which lack ERa (Figure 3B insert, lane 2) . Cells infected with Ad-ERa produced ERa ( Figure 3B insert, lane +) and exhibited a greater induction of TNFa To determine if unliganded ER potentiates TNFainduction of the TNFa gene in a cell type that naturally expresses ERa, we studied MCF-7 cells. TNFa induced recruitment of ERa to the TNFa gene as demonstrated by the images of PCR products spanning the TNF-RE ( Figure 3C , insert, lane +) and confirmed by real-time quantitative PCR (qPCR) ( Figure 3C , bars). To explore if ERa acts as a coactivator in MCF-7 cells, we treated cells with ICI, which causes ER degradation (Fan et al., 2003) . ICI produced a marked reduction in ERa levels as determined by immunoblotting ( Figure 3D , insert, lane +), which coincided with a lower induction of TNFa mRNA compared to untreated MCF-7 cells (Figure 3D, bars) . A similar reduction in TNFa activation of the TNFa gene occurred in MCF-7 cells expressing lower levels of ERa ( Figure 3E , insert) after treatment with short interfering RNA (siRNA) to ERa (Figure 3E, bars) . No decline in TNFa activation of TNFa mRNA occurred with control siRNA to maltose binding protein (MBP). Furthermore, siRNA to ERa did not inhibit TNFa activation of the TNFa gene in ER negative MDA-MB-435 cells ( Figure 3F ). This data provide further evidence that unliganded ERa acts as a coactivator by potentiating the stimulatory effects of TNFa.
Unliganded ER Does Not Potentiate TNFa-Induced Transcription of the TNFa Gene by Recruiting p160 Coactivators or CBP Membrane receptors signaling pathways activate unliganded nuclear receptors (Power et al., 1991) , which can stimulate transcription by recruiting p160 coactivators to AF-1 of ER (Dutertre and Smith, 2003; Webb et al., 1998) . To investigate if the coactivator activity of ERa is due to the recruitment of p160s, Flag-ERa cells were treated with TNFa for 3 hr and then ChIP was performed by using antibodies to Flag-ERa or p160s (Anzick et al., 1997; Hong et al., 1996; Smith and O'Malley, 2004; Voegel et al., 1996) . As previously shown, TNFa recruited ERa, but not the p160s, SRC-1, GRIP1 (TIF2/NcoA2/ SRC-2), or AIB1 (SRC-3) ( Figure 4A , lane 2). These results demonstrate that ERa does not enhance TNFainduced transcription of the TNFa gene by recruiting these coactivators. Another possibility is that ERa activates the TNFa gene by recruiting CBP (Kamei et al., 1996) . ChIP shows that TNFa recruited CBP in U2OS-ERa cells ( Figure 4A , lane 2), but recruitment was also observed in cells not induced with doxycycline to produce ERa ( Figure 4B , lane +). These studies provide evidence that the coactivation activity of unliganded ER is not likely due to the recruitment of p160s or CBP.
TNFa Assembles a Complex at the Promoter that Includes Unliganded ERa, Hsp90, and CBP but not GRIP1 In addition to ERa and CBP, TNFa recruited heat shock protein 90 (Hsp90), but not GRIP1, to the TNFa gene ( Figure 4A , lanes 2). We used re-ChIP to determine if these factors are recruited simultaneously to the TNFa promoter. Similar to ChIP data from the Flag-ERa cells, re-ChIP data show that TNFa recruited unliganded ERa and Hsp90 simultaneously to the TNFa promoter in the U2OS-ERa cells ( Figure 4C ). These results provide additional evidence that unliganded ERa is recruited to the TNFa promoter, because Hsp90 is known to interact with unliganded nuclear receptors (Pratt, 1997) . TNFa also induced the simultaneous recruitment of ERa and CBP ( Figure 4D ), but not CBP and GRIP1 (Figures 4E). The combined data from ChIP and re-ChIP studies Figure 3 . Unliganded ERa Potentiates TNFa Activation of the TNFa Gene (A) U2OS-ERa or wild-type (wt) U2OS cells were treated for 18 hr with the indicated concentration of doxycycline. TNFa (0.1 ng/ml) was added for 3 hr, and qPCR was used to measure TNFa mRNA levels. (B) Wt U2OS cells were infected for 24 hr with 50 MOI Ad-ERa or Ad-LacZ and then treated with 0.25 ng/ml TNFa for 2 hr. TNFa mRNA was determined by qPCR. Immunoblotting of cell extracts from cells infected with Ad-LacZ (2) or Ad-ERa (+) was done with an ERa antibody (insert). (C) ChIP was done in MCF-7 cells in the absence or presence of TNFa (3 hr treatment) by using an ERa antibody. PCR products were visualized with ethidium bromide (insert) or were measured by qPCR (bars). (D) MCF-7 cells were treated with ICI for 24 hr. TNFa was added for 2 hr, and TNFa mRNA was determined by qPCR. ERa protein expression was assessed by immunoblotting (insert). (E) ERa or MBP siRNA were transfected at the amount indicated into MCF-7 or (F) MDA-MB-435 cells for 4 days. Cells were treated with TNFa for 2 hr. TNFa mRNA was measured by qPCR. Immunoblots were performed by using cell extracts from siRNA transfected cells. Relative levels of ERa were detected with an ERa antibody. Error bars represent the mean 6SEM.
demonstrate that TNFa assembles a complex at the TNFa promoter that includes c-jun, p50-NFkB, p65-NFkB, Hsp90, CBP, and unliganded ERa, which are likely responsible for the marked induction of the TNFa gene by TNFa.
E 2 Recruits GRIP1 to the TNFa Promoter As E 2 did not alter recruitment of c-jun or NFkB by TNFa (Figure 2 ), it is unlikely that E 2 causes repression by interfering with binding of these factors to the TNFa promoter. To identify factors responsible for E 2 -mediated repression, U2OS-ERa cells were treated with TNFa in the absence or presence of E 2 . The addition of E 2 led to the recruitment of GRIP1, but not SRC-1, AIB1, or the corepressor, NCoR ( Figure 4A, lane 3 ). Re-ChIP shows that in the presence of E 2 , GRIP1 and CBP are simultaneously present at the TNFa promoter ( Figure 4E ), demonstrating that E 2 recruits GRIP1 to the transcriptional activation complex created by TNFa. Consistent with our ChIP data showing the loss of ERa with recruitment of GRIP1, re-ChIP indicates that ERa and GRIP1 are not present together at the promoter ( Figure 4F ).
The apparent loss of ERa after E 2 treatment from the promoter by ChIP (Figures 2 and 4) could result from receptor degradation, the dismissal of ERa from the promoter, or masking of epitopes for ERa antibodies after GRIP1 is recruited. Immunoblotting shows that ERa levels were stable during E 2 treatment ( Figure 4G ), demonstrating that the loss of ERa is not due to enhanced ERa degradation. To explore if ERa is masked after E 2 treatment, DNA pull-down assays were performed by using a biotinylated double-stranded oligonucleotide containing the TNF-RE. Immunoblots of proteins captured by the TNF-RE show that ERa is present in nuclear extracts prepared from cells treated with TNFa alone or TNFa and E 2 , but not untreated cells ( Figure 4H ). These results suggest that despite the disappearance of ERa by ChIP, it is possible that ERa remains at the promoter with E 2 but is masked by GRIP1 during ChIP.
GRIP1 Acts as a Corepressor of E 2 -Mediated
Repression of the TNFa Gene Our data showing that tamoxifen did not cause repression of the TNFa gene ( Figure 1C ) or recruit GRIP1 ( Figure 4A , lane 4) to the promoter suggest that GRIP1 is required for repression by E 2 . A requirement for GRIP1 in repression is supported by our findings with U2OS cells stably transfected with Flag-ERa containing a mutation in helix 3 (K362A) of AF-2, which is known to impair binding of p160s Henttu et al., 1997) . E 2 did not repress the TNFa gene in Flag-ERa-K362A cells ( Figure 5A ). ChIP shows that TNFa recruited unliganded ERa-K362A to the TNFa gene, but E 2 did not recruit GRIP1 ( Figure 5B ). These results demonstrate that repression by E 2 only occurs when GRIP1 is recruited. To further explore a functional role for GRIP1 in a setting where the AF-2 surface of ERa is not destroyed, we used RNA interference (RNAi) to silence GRIP1. Two lentiviruses expressing short hairpin RNA (shRNA) directed to different regions of the GRIP1 were infected sequentially in U2OS-ERa cells prior to selection with puromycin. No differences in TNFa activation of the TNFa gene was observed in cells infected with scrambled or GRIP1 shRNA compared to uninfected U2OS-ERa cells (data not shown). Furthermore, the magnitude of repression by E 2 in the cells expressing the scrambled shRNA was the same as the uninfected U2OS-ERa cells. These results demonstrate that the shRNA did not exhibit any nonspecific effects. Western blot of proteins from U2OS-ERa cells expressing shRNA to GRIP1 showed a 76% knockdown of GRIP1 by quantitative chemiluminescence compared to cells Figure 4 . TNFa Recruits Unliganded ERa, Hsp90, and CBP to the TNFa Gene (A) U2OS-Flag-ERa cells were treated with 5 ng/ml TNFa for 3 hr followed by 100 nM E 2 or 1 mM tamoxifen for 2 hr. ChIP was performed with antibodies to Flag-ERa, GRIP1, SRC-1, AIB1, CBP, NCoR, or Hsp90. Immunoprecipitated chromatin fragments were amplified by PCR, and the products were visualized with ethidium bromide. (B) U2OS-ERa cells not induced with doxycycline were untreated (2) or treated with (+) TNFa for 2 hr. ChIP was done by using an antibody to CBP. DNA fragments were amplified by PCR with primers for the TNF-RE. (C-F) For re-ChIP studies, cells were treated with 5 ng/ml TNFa for 3 hr followed by 100 nM E 2 for 2 hr and subjected to ChIP. After primary immunoprecipitation, crosslinked complexes were eluted and reimmunoprecipitated with a second antibody. The two antibodies used are indicated in the figures. The reimmunoprecipitated material was used for semiquantitative PCR (insert) and qPCR (bars). (G) U2OS-ERa cells were treated with doxycycline for 18 hr followed by 100 nM E 2 for the indicated time. ERa was detected by immunoblotting with an ERa antibody. (H) U2OS-ERa cells were induced with doxycycline and then treated with TNFa and E 2 as indicated. Nuclear extracts were incubated with a biotinylated oligonucleotide containing the TNF-RE attached to streptavidin-coated magnetic beads. The eluted proteins were separated by SDS-PAGE, and immunoblotting was done with an ERa antibody. expressing a scrambled shRNA ( Figure 5C ). E 2 inhibited the TNFa activation of the TNFa gene by 90% in U2OS-ERa cells expressing scrambled shRNA ( Figure 5D ). In cells expressing shRNA to GRIP1, only a 45% inhibition was observed. Silencing of GRIP1 also caused a partial reversal of E 2 repression of other cytokine genes activated by TNFa, including colony stimulating factor-2 (CSF2), small inducible cytokine A4 (SCYA4), and interleukin-8 (IL-8) ( Figure 5D ). The incomplete reversal of repression by E 2 is most likely due to the presence of residual GRIP1 protein ( Figure 5C ). These results demonstrate that silencing of GRIP1 results in a reduction of E 2 -mediated repression of TNFa activation of cytokine genes.
Discussion
Understanding how estrogens repress cytokine genes is important because cytokines have been implicated in a variety of inflammatory diseases that increase after menopause (Pfeilschifter et al., 2002) . To address the paucity of information on the mechanism of repression of cytokine genes by estrogens, we used ChIP to identify the factors involved in repressing the TNFa gene.
TNFa Recruits Unliganded ER to a Platform Made of c-jun and NFkB
Our ChIP data demonstrated that TNFa recruits the transcription factors c-jun, p50-NFkB, p65-NFkB, and CBP to the promoter, which participates in the induction of the TNFa gene. Unexpectedly, TNFa also recruited unliganded ER along with Hsp90 to the TNFa promoter. Pull-down assays (Stein and Yang, 1995) , our previous studies showing that mutations in the c-jun and NFkB sites abolish E 2 repression of the TNFa promoter (Tzagarakis- Foster et al., 2002) , and coimmunoprecipitation data from this study indicate that ER interacts with a platform made of c-jun and NFkB. A requirement for the formation of this platform prior to ER binding is supported by our kinetic ChIP data that shows ER is recruited to the TNFa gene slower than c-jun, p50-NFkB, and p65-NFkB. These studies suggest that a major role of c-jun and NFkB is to tether unliganded ER to the TNFa promoter.
The mechanism whereby TNFa induces protein-protein interactions between ER, c-jun, and NFkB is unclear. Unliganded nuclear receptors are activated by signal transduction pathways (Power et al., 1991) such as MAPK that phosphorylates ER (Improta-Brears et al., 1999; Kato et al., 1995; Le Goff et al., 1994) . TNFa activates MAPK (Wajant et al., 2003) , but it did not induce phosphorylation of ser-118 or ser-167. These results suggest that other signal transduction pathways activate ERa in U2OS cells. In contrast to the TNFa gene, TNFa did not recruit unliganded ER to the keratin 19 gene, which is activated by E 2 . These findings suggest that in U2OS cells, TNFa selectively recruits unliganded ER to genes repressed by E 2 , but not to genes activated by E 2 .
Unliganded ER Acts as a Coactivator at the TNFa Promoter
Once TNFa recruits unliganded ERa to the promoter, we demonstrated that ER acts as a coactivator. We showed that ERa produced a marked enhancement of the TNFamediated increase in TNFa mRNA in inducible-U2OS cells that expressed increasing levels of ERa with doxycycline or in wild-type U2OS cells infected with an adenovirus that expresses ERa. Furthermore, a loss of ERa in MCF-7 cells by ICI or siRNA resulted in a diminished TNFa induction of the TNFa gene. To our knowledge, the coactivator property of unliganded ER at promoters has not been reported for genes repressed by estrogens. Thus, our studies demonstrate that ERa acts as a TNFa-activated coactivator and reveal a unique transcriptional activity for ER.
The N-terminal AF-1 domain of ER is capable of recruiting p160 coactivators (Dutertre and Smith, 2003; Webb et al., 1998) . By contrast, no evidence was found in our ChIP studies for TNFa recruitment of p160s to unliganded ER. Furthermore, re-ChIP data showed that ER and GRIP1 were not at the TNFa promoter simultaneously, demonstrating that unliganded ER has a conformation that is unable to interact with p160 coactivators when tethered to the TNFa promoter. We also found that TNFa recruits CBP in the absence of ER. These results demonstrate that the coactivator activity of ER is not likely due to the recruitment of p160s or CBP. Alternatively, ER may enhance the activation of the TNFa gene through an intrinsic coactivator mechanism, the recruitment of other p160 coactivators not tested, or by enhancing the activation function of CBP, c-jun, NFkB, or other factors bound to the TNFa promoter.
E 2 Initiates Repression by Recruiting GRIP1, which Acts as a Corepressor Transfection studies suggested that E 2 inhibits the activation of cytokine genes by interfering with the binding of NFkB (Galien and Garcia, 1997; Stein and Yang, 1995) . However, this is an unlikely mechanism whereby E 2 represses the TNFa gene, because ChIP showed that E 2 did not impair the binding of p55-NFkB or p65-NFkB. Another possible mechanism is that E 2 causes repression by recruiting corepressor proteins such as NCoR, which mediates transcriptional repression by unliganded nuclear receptors (Chen et al., 1996; Horlein et al., 1995) and ER and progesterone receptor antagonists (Zhang et al., 1998) . NCoR is also required for the repression of inflammatory genes by PPAR-g agonists in macrophages (Pascual et al., 2005) . However, our studies suggest that NCoR is not involved in estrogenmediated repression of cytokine genes. We previously found that overexpressing NCoR did not potentiate the repression of the TNFa promoter by E 2 in transfection studies . A lack of a role for NCoR in repression is consistent with the finding that E 2 did not recruit NCoR to the TNFa gene. The findings with PPAR-g (Pascual et al., 2005) and ours with ER indicate that agonist-mediated repression by nuclear receptors can occur by distinct mechanisms.
Our studies provide evidence that E 2 triggers repression by binding to ER already present at the promoter. Once ER is liganded with E 2 , it recruits GRIP1, which mediates repression of the TNFa gene. A role for GRIP1 in E 2 -mediated repression was supported by the observation that no recruitment of GRIP1 occurred with tamoxifen, which is known to block p160 interactions with ER (Brzozowski et al., 1997; Shiau et al., 1998) . Also, a mutation in helix 3 of ER that disrupts the AF-2 surface Henttu et al., 1997) prevented the recruitment of GRIP1. In both cases, repression did not occur when there was no recruitment of GRIP1. Because it is possible that ER must be in an active conformation to induce repression, we also used RNAi to explore the role of GRIP1 in repression. Silencing of GRIP1 reversed the repression of TNFa and other cytokine genes by E 2 . The series of studies with tamoxifen, the helix 3 mutant, and RNAi demonstrate that GRIP1 functions as a corepressor of cytokine genes repressed by estrogens.
GRIP1 May Be a Unique p160 Protein that Can Act as a Coactivator or Corepressor
Other members of the p160s, including SRC-1 (Onate et al., 1995) and AIB1 (Anzick et al., 1997) , were not recruited to the TNFa gene. These findings suggest that GRIP1 is selectively recruited to genes repressed by E 2 and that GRIP1 can function as a coactivator or corepressor, whereas SRC-1 and AIB1 function only as coactivators in U2OS cells. This notion is supported by our RNAi data that suggest other coactivators cannot substitute for GRIP1, because if GRIP1 was redundant then no reversal of repression should have occurred in cells depleted of GRIP1 by RNAi. The finding that GRIP1 has a markedly different amino acid composition compared to SRC-1 and AIB1 in a region linked to glucocorticoid receptor (GR) repression of gene transcription also suggests that p160s possess distinct activities (Rogatsky et al., 2002) .
Two activation domains (AD1 and AD2) are present in the C-terminal domain of GRIP1 (Hong et al., 1996; Voegel et al., 1996) and activate target genes by recruiting acetyltransferases (Kamei et al., 1996; Ogryzko et al., 1996) and methyl-transferases (Chen et al., 1999) . Deletion of both AD1 and AD2 does not affect ER (data not shown) or GR-mediated repression in transfection studies (Rogatsky et al., 2002) , indicating that the region of GRIP1 involved in repression is distinct from activation. These findings suggest that GRIP1 may be a unique p160 protein that acts as a corepressor in genes repressed by some steroid receptors.
ER Disappears from the TNFa Promoter with E 2 Treatment
Our ChIP data showed that E 2 -mediated recruitment of GRIP1 is associated with the loss of ER from the TNFa gene. By contrast, E 2 induced recruitment of both ER and GRIP1 to the keratin 19 gene, which is consistent with data derived from other genes activated by ER (Metivier et al., 2003; Shang et al., 2000) . We showed that the loss of ER was not due to receptor degradation. Another possible explanation is that the epitopes recognized by the ER antibodies were masked when GRIP1 interacts with the ER. This is consistent with the observation that the ERa helix 3 mutant does not disappear from the TNFa promoter when GRIP1 is not recruited. Our DNA pull-down assays with the TNF-RE linked to streptavidin-coated magnetic beads showed that nuclear extracts derived from cells treated with TNFa alone or TNFa and E 2 contained ERa that bound to the TNF-RE. These findings support the data with the helix 3 mutant, indicating that ER remains at the promoter with E 2 treatment but that the epitopes for ER antibodies are being masked during ChIP.
Whereas our studies were unable to determine the mechanism for the disappearance of ERa from the promoter, the observation that ER disappears when using the flag antibody and three antibodies against different epitopes to ERa in the amino-or carboxy-terminal domain and also antibodies to ERb favors the view that ER is dismissed from the promoter. If ER were actually dismissed, then GRIP1 would have to be tethered to a factor other than ER once a required surface is cleared of ER. The dismissal of ER from the TNFa promoter would abolish the coactivator activity of ER and could also serve the purpose of making ER available to other target genes.
Potential Mechanisms whereby GRIP1 Acts as a Corepressor
The mechanism whereby GRIP1 acts as a corepressor at the TNFa gene is not known. It is possible that GRIP1 interferes with the coactivator activity of unliganded ER, the activation function of transcription factors, such as c-jun, NFkB, or CBP, or factors bound to the TNFa promoter involved in transcriptional regulation. Our findings showing that E 2 causes opposite effects on the recruitment of ER to the TNFa and keratin 19 genes indicate that the conformation of GRIP1 is different when it acts as a corepressor instead of a coactivator. When GRIP1 is bound to genes activated by E 2 , its conformation exposes surfaces that facilitate recruitment of activators such as histone acetyltransferases and methyl-transferases (Metivier et al., 2003; Shang et al., 2000) . In contrast, our studies suggest that when GRIP1 is associated with the TNFa promoter, different surfaces are exposed that might recruit repressor proteins that are actually responsible for repression of the TNFa gene.
Clinical Implications of Unliganded and Liganded ER Regulation of the TNFa Gene
Whereas it is known that the decline of estrogens during menopause can lead to osteoporosis and other diseases associated with menopause, our findings raise the unexpected possibility that unliganded ERs contribute to some menopausal conditions. The lack of estrogens in postmenopausal women could lead to unopposed coactivator activity of ERs that persist in tissues in response to TNFa. Based on our studies, this would enhance the induction of the TNFa gene and increase TNFa production in tissues and thereby promote inflammation and tissue injury. In contrast, prior to menopause, higher levels of estrogens will result in the formation of liganded ERs that recruit GRIP1, which acts a corepressor by reversing the coactivator activity of ER and the stimulatory effects of the c-jun, NFkB, and CBP on the transcription of inflammatory genes, such as TNFa. By understanding the mechanisms whereby estrogens repress cytokine genes, it may be possible to develop repression-selective estrogens that retain anti-inflammatory properties, but do not activate genes known to promote cancer.
Experimental Procedures
Preparation of Stable Lines U2OS cells stably expressing tetracycline-inducible ERa or ERb were prepared as previously described (Kian Tee et al., 2004) . Flag-tagged cells were made by transfecting wild-type U2OS cells with pcDNA 6/V5-His (Invitrogen) containing cDNAs for Flag-ERa, Flag-ERb, or Flag-ERa helix 3 mutant (K362A). The Flag-tag was inserted at the N terminus of ERs. Stable Flag-tagged cell lines were selected with 10 mg/ml blasticidin (Invitrogen).
Quantitative Real-Time PCR Total RNA was prepared by using TRIzol (Invitrogen) as previously described (Paruthiyil et al., 2004) . qPCR detection of TNFa mRNA was performed with a BioRad iCycler Thermal Cycler System with a TNFa TaqMan assay kit (Applied Biosystems). Control reactions were performed by using primers and a probe to detect b-glucoronidase (Gus). Primers for Gus were: forward, 5 0 -CTCATTTGGAATTTT GCCGATT-3 0 ; reverse, 5 0 -CCGAGTGAAGATCCCCTTTTTA-3 0 (Operon). qPCR detection of keratin19, CSF2, SCYA4, and IL-8 mRNA was performed with the iQ SYBR Green Supermix (Bio-Rad Estrogen Receptor Binding Assay U2OS-ERa stable cells were treated overnight with doxycycline (0.1 ng -1 mg/ml). Cells were then incubated for 2 hr at 37ºC with 20 nM [ 3 H] E2 (NEN, specific activity 87.6 Ci/mmol) in the absence or presence of 100-fold excess of unlabeled E 2 . After washing with 0.1% bovine serum albumin in phosphate buffered saline, the cells were dissolved in SDS lysis buffer (0.5% SDS, 0.05 M Tris-HCl [pH 8.0], and 1 mM DTT). Specific binding was calculated as the difference between total and nonspecific binding and expressed as cpm/1.5 million cells.
Western Blotting Analysis
Total proteins (15 mg) from cells were separated with 4%-12% gradient Bis-Tris gels (Invitrogen). Proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Perkin Elmer) and incubated with anti-ERa (DAKO), anti-Phospho-ERa (Ser-118) (Cell Signaling), or anti-Phospho-ERa (Ser-167) (Cell Signaling) diluted 1:1000 in blocking buffer followed by anti-mouse IgG conjugated with horseradish peroxidase (PharMingen). An ECL detection system (Amersham Biosciences) was used to visualize the proteins.
Coimmunoprecipitation Cells were treated with doxycycline for 18 hr and TNFa for 2 hr. Cells were lysed in RIPA buffer (150 mM NaCl, 1% Triton X-100, 50 mM Tris-HCl, and protease inhibitors), and extracts (500 mg) were incubated with a p50-NFkB, p65-NFkB (Upstate Biotechnology), or c-jun (Santa Cruz Biotechnology) antibody and protein G agarose overnight at 4ºC. Immunoprecipitated proteins were separated by sodium dodecyl-sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a PVDF membrane. Blots were incubated with ERa antibody (DAKO) and detected with the ECL system (Amersham BioSciences).
RNA Interference
MCF-7 or MDA-MB-435 cells were plated in 4% charcoal dextran stripped FBS-DMEM/F-12 media and grown to 50% confluency. Cells were transfected with ERa ShortCut siRNA Mix or MBP shortcut siRNA mix as a negative control (New England Biolabs). After 48 hr, a second transfection was performed for a total of 4 days. Cells were treated with TNFa (5 ng/ml) for 2 hr, and then RNA or protein were prepared for qPCR and Western blots, respectively.
Plasmid Construction, Virus Production, and Cell Culture Adenovirus expressing ERa was prepared as previously described (Paruthiyil et al., 2004) . The lentiviruses were produced with PCR products containing the U6 promoter and a shRNA (Li et al., 2004) to two different regions of GRIP1. The primers used were: 5 0 -AAA ACTGCAGAAAAAGGAATGTCCTGACCAACTTGGACCCTCTCTTGA AGGGTCCTAGTTGGTGAGGACATTCCGGTGTTTCGTCCTTTCCAC AAG-3 0 or 5 0 -AAAACTGCAGAAAAAGTGCAGAAGTCAGATGTATCC TCTATCTCTTGAATAGAGGTTACATCTCACTTCTGCACGGTGTTTC GTCCTTTCCACAAG-3 0 and 5 0 -AAAAACTAGTAAGGTCGGGCAGGA AGAGGGC-3 0 . The two PCR products were subcloned into the pHRCMVPUROWSin18 vector and then transfected into HEK293 T cells along with pMD.G1 and pCMVDR8.91 (generously provided by Dr. Didier Trono, University of Geneva). After 48 hr and 72 hr, the culture medium containing the lentivirus expressing GRIP1 shRNA was harvested. U2OS-ERa cells were infected with a lentivirus expressing a scrambled shRNA (generously provided by Dr. Alex So, University of California, San Francisco) or sequentially with two different lentiviruses expressing GRIP1 shRNA. After infection, cells were selected with 3 mg/ml puromycin.
ChIP and Re-ChIP Cells were treated as indicated in legends and then were crosslinked, washed, collected, and lysed as previously described (Burakov et al., 2002; Kian Tee et al., 2004) . Immunoprecipitations were performed overnight at 4ºC with anti-p50 NFkB, anti-p65 NFkB, anti-SRC-1 (clone 1135) (Upstate Biotechnology), anti-c-jun (H-79), anti-CBP (A-22), anti-N-CoR (C-20), anti-ERa (HC-20) (Santa Cruz Biotechnology), anti-flag M2 (Sigma-Aldrich), anti-GRIP1 (ab9261), anti-AIB1 (ab2782) (Abcam), anti-ERa (1D5) (DAKO), antiERa (MSERA11-UP50), anti-ERb (6A12, 14C8 and 7B10) (GeneTex, Inc), and anti-Hsp90 (AC88) (StressGen). The 2167 to +42 region of the TNFa gene was amplified with the primers 5 0 -CCCCGCGATG GAGAAGAAACCGAGA-3 0 and 5 0 -GCTGGTCCTCTGCTGTCCTTGCT GA-3 0 . The primers used to amplify the keratin 19 estrogen response element (ERE) (Choi et al., 2000) were: forward, 5 0 -TCCAGCCTGGGT GACAGAGC-3 0 ; and reverse, 5 0 -TCCAAGTTCACCCCAACCTGA-3 0 . For re-ChIP experiments, after primary immunoprecipitation, crosslinked complexes were eluted from the immunoprecipitate and were reimmunoprecipitated with the second antibody as previously described (Metivier et al., 2003) . The copy number of the samples was calculated by qPCR from a standard curve prepared by using a serial titration of the plasmid containing the TNF-RE. The final results were expressed as the percentages of the initial inputs.
DNA Pull-Down Assays U2OS-ERa cells were induced with doxycycline for 18 hr and then treated with TNFa in the absence or presence of E 2 . Nuclear extracts were prepared as described in the mMACS Streptavidin Kit protocol (Miltenyi Biotec) with the exception that the nuclei were not sonicated. A biotinylated synthetic oligonucleotide containing the TNF-RE (forward, 5 0 -Bio/GGTACCGAGCTCTTACGCGTGCACTACC GCTTCCTCCAGATGAGCTCATGGGTTTCTCCACCAAGCTCGAGAT CT-3 0 ; reverse, 5 0 -AGATCTCGAGCTTGGTGGAGAAACCCATGAGC TCATCTGGAGGAAGCGGTAGTGCACGCGTAAGAGCTCGGTACC-3 0 ) was annealed and incubated with mMACS Streptavidin MicroBeads. Proteins in the nuclear extracts were captured with MicroBeads, eluted, and separated on SDS-PAGE. Western blots were done with antibodies to ERa.
